ANAL CANCER

This study tests the drug pembrolizumab in about 1,600 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors and to identify biomarkers that predict response. Participants receive pembrolizumab and are m…

This early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This study tests whether a mix of three immunotherapy drugs can shrink tumors in people with advanced HPV-related cancers that have spread. About 51 adults with cancers like cervical, anal, or throat cancer will receive the drugs for up to a year. The goal is to control the disea…

This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in adults with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system to fight the cancer better. Participants …

This study tests a combination of three drugs (entinostat, PDS01ADC, and bintrafusp alfa) in adults with advanced cancers linked to HPV or certain colon cancers that haven't responded to standard treatments. The goal is to find a safe dose and see if the treatment can shrink tumo…

This study is testing whether giving a lower dose of radiation to nearby lymph nodes during standard chemoradiation for anal cancer can reduce side effects like diarrhea, bladder issues, and skin problems. About 33 adults with locally advanced anal cancer will receive the reduced…

This study explores whether a special type of radiation therapy can protect the ovaries of young women (ages 18-50) undergoing pelvic radiation for cancers like uterine, rectal, or cervical cancer. The goal is to see if doctors can consistently see the ovaries on daily scans and …

This study tests a program called Potlako+ that combines community education, help for healthcare workers, and patient guides to speed up cancer detection and treatment. About 874 adults in Botswana with possible cancer symptoms will take part. Half of the communities get the pro…